“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Acorda Therapeutics


Acorda Therapeutics – A to Z Product Catalog

  • Ampyra® (dalfampridine ER tablets)
    • Generic: Dalfampridine (4-aminopyridine) extended-release
    • Indication: Improves walking speed in multiple sclerosis patients
    • Dose: 10 mg orally every 12 hours (max 20 mg/day)

  • BTT1023 (Timolumab)
    • Type: Monoclonal antibody
    • Indication: Investigated for primary sclerosing cholangitis
    • Dose: Investigational, not approved

  • CVT-427
    • Generic: Zolmitriptan (inhaled, ARCUS delivery)
    • Indication: Acute migraine treatment (investigational)
    • Dose: Investigational, not approved

  • Inbrija® (levodopa inhalation powder)
    • Generic: Levodopa (oral inhalation)
    • Indication: Intermittent treatment of “OFF” episodes in Parkinson’s disease
    • Dose: Inhaled as needed during OFF episodes, alongside regular oral levodopa

  • rHIgM22
    • Type: Remyelinating monoclonal antibody
    • Indication: Investigational for multiple sclerosis remyelination
    • Dose: Investigational, not approved

  • Tozadenant (SYN115)
    • Type: Adenosine A₂A receptor antagonist
    • Indication: Investigational for Parkinson’s disease (development discontinued)
    • Dose: Investigational, not approved

  • Zanaflex® Capsules
    • Generic: Tizanidine hydrochloride
    • Indication: Muscle spasticity (e.g., MS, spinal cord injury)
    • Dose: 2–4 mg orally up to 3 times daily as needed


    • on

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)